Compare TEVA & CQP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TEVA | CQP |
|---|---|---|
| Founded | 1901 | 2003 |
| Country | Israel | United States |
| Employees | 32842 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil/Gas Transmission |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.7B | 34.0B |
| IPO Year | N/A | 2006 |
| Metric | TEVA | CQP |
|---|---|---|
| Price | $29.66 | $68.99 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 8 | 7 |
| Target Price | $37.38 | ★ $58.86 |
| AVG Volume (30 Days) | ★ 6.7M | 114.6K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 4.94% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $10,758,000,000.00 |
| Revenue This Year | N/A | $5.49 |
| Revenue Next Year | $2.51 | $1.69 |
| P/E Ratio | ★ $28.19 | $962.00 |
| Revenue Growth | N/A | ★ 23.60 |
| 52 Week Low | $12.47 | $49.53 |
| 52 Week High | $37.35 | $70.64 |
| Indicator | TEVA | CQP |
|---|---|---|
| Relative Strength Index (RSI) | 41.72 | 69.26 |
| Support Level | $28.38 | $51.48 |
| Resistance Level | $31.99 | N/A |
| Average True Range (ATR) | 0.99 | 2.01 |
| MACD | -0.02 | 0.36 |
| Stochastic Oscillator | 42.11 | 85.37 |
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Cheniere Energy Partners is a liquified natural gas producer operating one facility in Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed- and variable-fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. The profit generated through those activities is split with parent and operator Cheniere Energy.